GSK (LSE:GSK) delivered a robust third-quarter 2025 performance, with sales rising to £8.5 billion, fueled by strong demand across its specialty medicines, vaccines, and general medicines divisions. The company raised its full-year guidance, now expecting turnover growth of 6–7%, core operating profit growth of 9–11%, and core EPS growth of 10–12%.
The results were driven by double-digit gains in respiratory, oncology, and HIV treatments, reflecting GSK’s focus on innovation and expansion in high-growth therapeutic areas. The company also benefited from continued momentum in its vaccine portfolio, including products for meningitis and shingles.
During the quarter, GSK secured four new product approvals and reported progress in multiple late-stage clinical trials, positioning it for future growth. CEO Emma Walmsley highlighted that ongoing investments in R&D and pipeline development are “building sustainable long-term value for patients and shareholders alike.”
In line with its capital return strategy, GSK declared a dividend and continued its share buyback program, emphasizing its commitment to shareholder returns.
More about GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a global biopharmaceutical company focused on developing and manufacturing specialty medicines and vaccines that address major diseases. Its core therapeutic areas include respiratory, oncology, immunology, and HIV, complemented by a leading vaccine portfolio. Headquartered in London, GSK operates worldwide with a mission to unite science, technology, and talent to get ahead of disease together.
Leave a Reply